80 results
Page 2 of 4
6-K
EX-99.3
yul8 imflo8m2
30 Nov 23
Current report (foreign)
11:19am
6-K
ax8nl 41i
30 Nov 23
Current report (foreign)
11:19am
6-K
EX-99.2
9tcelc
30 Nov 23
Current report (foreign)
11:19am
6-K
EX-99.1
r2ifl4o7t025q83n
2 Nov 23
MorphoSys To Showcase Phase 3 MANIFEST-2 Data on Pelabresib in Myelofibrosis in Oral Presentation at 2023 ASH Annual Meeting
9:20am
6-K
EX-99.1
x3ebwbu7mdel
11 May 23
MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
1:12pm
6-K
EX-99.1
nibu4yi3ju mjo3ke496
4 May 23
First Quarter Interim Statement January – March
9:24am
6-K
EX-99.1
mbzhw9o5x fs
17 Apr 23
Current report (foreign)
8:13am
6-K
EX-99.1
zez5r89t0o3aj000uw
4 Apr 23
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
4:09pm
6-K
EX-99
antkylbk hebdkt
12 Dec 22
MorphoSys Presents Updated Tafasitamab Results in Newly Diagnosed DLBCL Patients from Final firstMIND Analysis at ASH 2022
6:14am
6-K
EX-99.1
ygjogjuw
16 Nov 22
Third Quarter Interim Statement January – September
4:14pm
6-K
EX-99.1
y09yzjn1m 0x1ru5c
3 Nov 22
MorphoSys to Share New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) in 14 Presentations at the American Society of Hematology Annual Meeting
9:40am
6-K
EX-99.1
iuji3fi
28 Sep 22
Current report (foreign)
5:04pm
6-K
EX-99.1
46e zbi76vlu
3 Aug 22
Half-Year Report JANUARY – JUNE 2022
4:36pm
6-K
EX-99.1
fakh0qbb
23 Jun 22
First Quarter Interim Statement JANUARY – MARCH
6:30am
6-K
EX-99.1
67i2v8
12 May 22
Current report (foreign)
10:53am
6-K
EX-99.1
drs7bjd56dqdoeu
23 Mar 22
Current report (foreign)
4:15pm
6-K
EX-99.1
3we6rc6s4
16 Mar 22
Current report (foreign)
5:13pm
6-K
EX-99.1
abqne9soki0ih ro1m
16 Mar 22
2021 Annual Report A nn ua l R ep or t 20 21
4:55pm
6-K
EX-99.1
y9achau98rwkmdobb
15 Mar 22
Current report (foreign)
4:12pm